Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

NCT02183610 | Completed Phase 1

• 1 other identifier: 1218.7
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

To determine the basic pharmacokinetics of BI 1356 BS, its metabolite CD 1750 XX and radioactivity including excretion mass balance, excretion pathways and metabolism following the intravenous and oral administration of \[14C\] BI 1356 BS

Conditions

Healthy

Outcome Measures

Primary Outcomes (18)

• Comparison of individual time course profiles of [14C] radioactivity in whole blood, plasma, urine and faeces

  before and up to 264 h after drug administration

• Comparison of individual time course profiles of BI 1356 BS and its metabolite CD 1750 XX in plasma and urine

  before and up to 264 h after drug administration

• Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces

  prior to and up to 120 h after start of administration

• CBlood cell/Cplasma ratio of [14C] -radioactivity

  1:30, 3, 24 and 72 h after drug administration

• Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo

  1:30 and 3 hours post drug administration

• Cmax (maximum concentration of the analyte(s) in plasma)

  before and up to 264 h after drug administration

• tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)

  before and up to 264 h after drug administration

• AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)

  before and up to 264 h after drug administration

• AUC0-infinity (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)

  before and up to 264 h after drug administration

• λz (terminal rate constant in plasma)

  before and up to 264 h after drug administration

• t1/2 (terminal half-life of the analyte(s) in plasma)

  before and up to 264 h after drug administration

• MRTpo and MRT, respectively (mean residence time of the analyte(s) in the body after p.o. and i.v. administration)

  before and up to 264 h after drug administration

• CL/F (apparent/total clearance of the analyte(s) in plasma following extravascular and intravenous administration)

  before and up to 264 h after drug administration

• Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular or intravenous administration (F=1) respectively)

  before and up to 264 h after drug administration

• feurine,0-tz (amount of analyte excreted in urine within the time interval zero to tz (=120 h) in % of dose)

  prior to and up to 120 h after start of administration

• fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz (=120 h) in % of dose)

  up to 120 h after drug administration

• CLR,0-tz (renal clearance of analyte)

  prior to and up to 120 h after start of administration

• Fa (drug absorption based on radioactivity data)

  up to 264 h after drug administration

Secondary Outcomes (3)

• Number of patients with adverse events

  up to 47 days

• Global assessment of tolerability by investigator on a 4-point scale

  on day 12 during ambulant visit or on day of discharge on day 13, 14 or 15

• Evaluation of local tolerability of the infusion by investigator on a 6-point scale

  after start of infusion up to day 15

Study Arms (2)

[14C] BI 1356 as oral (p.o.) solution

EXPERIMENTAL

Drug: [14C] BI 1356 as oral (p.o.) solution

[14C] BI 1356 solution for i.v. infusion

EXPERIMENTAL

Drug: [14C] BI 1356 solution for i.v. infusion

Interventions

[14C] BI 1356 as oral (p.o.) solution DRUG

[14C] BI 1356 as oral (p.o.) solution

[14C] BI 1356 solution for i.v. infusion DRUG

[14C] BI 1356 solution for i.v. infusion

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \- Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests
• Age \>=30 and Age \<=60 years
• BMI \>=18.5 and BMI \<=29.9 kg/m2 (Body Mass Index)
• Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation

You may not qualify if:

• Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
• Any evidence of a clinically relevant concomitant disease
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of relevant orthostatic hypotension, fainting spells or blackouts
• Chronic or relevant acute infections
• History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
• Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
• Participation in another trial with an investigational drug within two months prior to administration or during the trial
• Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
• Inability to refrain from smoking during the stay in the trial centre
• Alcohol abuse (more than 60 g/day)
• Drug abuse
• Blood donation (more than 100 mL within four weeks prior to administration or during the trial)

Sponsors & Collaborators

• Boehringer Ingelheim: lead

MeSH Terms

Interventions

Linagliptin; Solutions

Intervention Hierarchy (Ancestors)

Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Quinazolines; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2014
• First Posted: July 8, 2014
• Study Start: July 1, 2006
• Primary Completion: September 1, 2006
• Last Updated: July 8, 2014

Record last verified: 2014-07